Publicacions en què col·labora amb Jesús Santos González (12)

2024

  1. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain

    Viruses, Vol. 16, Núm. 2

2021

  1. Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic?

    International Journal of STD and AIDS, Vol. 32, Núm. 13, pp. 1257-1260

  2. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

    Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810

  3. Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain

    HIV Medicine, Vol. 22, Núm. 5, pp. 379-386

2019

  1. A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study)

    Liver International, Vol. 39, Núm. 10, pp. 1918-1926

  2. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients

    Medicine (United States), Vol. 98, Núm. 32

  3. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients

    HIV Medicine, Vol. 20, Núm. 6, pp. 359-367

  4. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort

    PLoS ONE, Vol. 14, Núm. 8

2017

  1. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8

2016

  1. Clinical, virological and phylogenetic characterization of a multiresistant HIV-1 strain outbreak in naive patients in southern Spain

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 2, pp. 357-361

2015

  1. Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term

    Hepatology, Vol. 61, Núm. 5, pp. 1503-1511

2013

  1. Risk of liver decompensation among HIV/Hepatitis C virus-coinfected individuals with advanced fibrosis: Implications for the timing of therapy

    Clinical Infectious Diseases, Vol. 57, Núm. 10, pp. 1401-1408